Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5052W HIGH $1.56
Volume
56.49 K
Value Traded
360.51 K
Short % Float
1.65%
-6.14%Week
+17.41%1 Month
+26.33%3 Month
+88.58%6 Month
-93.38%5 Year
-93.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
48.08 M
EPS (TTM)
-0.91
P/E Ratio
-
Ent. Value
72.61 M
Total Shares
45.14 M
Float Shares
33.41 M
Insiders
25.99%
Institutions
39.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TELA Catalyst Timeline
Dated clinical, regulatory and corporate events for TELA Bio, Inc.
Past FDA Catalysts and PDUFA Decisions
How TELA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
TELA Bio, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TELA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OviTex | Ventral Hernia Repair | 2020-09-25 | low incidence of surgical site infections and occurrences; none required surgical intervention or implant removal; 85 subjects; 75% met the criteria for Ventral Hernia Working Group (VHWG) grade 2 or grade 3; over 50% of the patients were obese; over one-third had undergone a previous ventral hernia repair; 16% had a history of surgical infections; no patient experienced a hernia recurrence within the first 30-days; no patient experienced a hernia recurrence among the initial 20 patients at two year follow up; five patients experienced an SSO during the two yearsRead More | TELA Bio Presents Additional Data from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, PARead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Capper Joseph HDirector | Buy | 25,000 179,827 held | $1.22 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TELA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.2 % (100 %) | 1.60 M | 2.14 M | -5.4% ( -122.11 K) |
TELA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TELA ranks across every disease it competes in
Competitive Position is a premium feature
See how TELA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTELA News
TELATELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
TELA Bio has received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh designed for soft tissue reinforcement. This marks a significant milestone as it is the first product developed in-house by TELA Bio. The company aims to enhance options for surgeons and patients in the soft tissue reconstruction market.
Read more →TELA▲ +5.4%on this news
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
TELA Bio announced the resignation of COO/CFO Roberto Cuca and a strategic cost reduction initiative. The company aims to reduce annual operating expenses by approximately $17 million, which includes a 20% workforce reduction. A one-time restructuring charge of $1.5 million is expected in Q3 2026. The initiative is designed to extend TELA's cash runway into 2028.
Read more →TELA▼ -6%on this news
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio has announced inducement grants of stock options and restricted stock units to its newly-hired CEO, Heather Getz, and other employees. The grants, totaling 2,370,000 stock options and 500,000 restricted stock units, are part of the company's strategy to attract talent. The options have a ten-year term and vest over four years.
Read more →TELA▲ +22.5%on this news
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
TELA Bio has appointed Heather Getz as its new Chief Executive Officer and Director. Getz, who previously held executive roles at Butterfly Network and BioTelemetry, is expected to drive the company's growth and enhance its impact in soft-tissue reconstruction. The Board expressed confidence in her leadership, while also acknowledging the contributions of former CEO Tony Koblish.
Read more →TELATELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TELA Bio, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The presentation is scheduled for 8:30 am ET, and interested parties can access the live and archived webcast. TELA Bio specializes in innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation.
Read more →TELATELA Bio to Announce Second Quarter 2026 Financial Results
TELA Bio, Inc. has announced that it will report its second quarter 2026 financial results on August 10, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. Interested investors can register online to participate in the call.
Read more →TELA▼ -5.9%on this news· ran to -19% by day 3
TELA Bio Reports First Quarter 2026 Financial Results
TELA Bio reported its first quarter 2026 financial results, showing a 3% revenue increase to $19.1 million. The company highlighted strong early productivity from new territory managers and successful international market penetration. However, net losses rose to $12.3 million, and gross margins decreased due to inventory charges. The company reiterated its financial guidance for 2026.
Read more →TELATELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
TELA Bio, Inc. has announced a strategic refreshment of its board of directors, with four new members joining to enhance the company's growth and operational capabilities. This change, effective after the 2026 Annual Meeting, aims to support TELA Bio's mission toward sustainable profitability and improved commercial strategies. Additionally, the company reported preliminary revenues of approximately $19.0 million for the first quarter of 2026, slightly exceeding previous guidance. Full financial results will be disclosed on May 12, 2026.
Read more →TELATELA Bio to Announce First Quarter 2026 Financial Results
TELA Bio, Inc. will announce its first quarter 2026 financial results on May 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a corporate update. Interested investors must register in advance to participate in the call.
Read more →TELA▼ -9.4%on this news· ran to -26% by day 3
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
TELA Bio reported strong financial results for Q4 and full year 2025, with revenues reaching $20.9 million in Q4, an 18% increase from the previous year. The company maintained flat operating expenses while expanding its sales team, which positions it for continued growth. However, it still reported a net loss, highlighting ongoing financial challenges.
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
TELA Bio, Inc. has announced it will report its fourth quarter and full year 2025 financial results on March 24, 2026. Management will participate in a conference call and webcast to discuss these results and provide a corporate update. The company specializes in innovative solutions for soft-tissue reconstruction while focusing on the preservation of patients' anatomy. Investors interested in the call are required to register in advance.
Read more →TELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 23, 2026
TELA Bio has announced the approval of inducement grants for five newly-hired employees, totaling 14,250 restricted stock units. These grants, effective January 20, 2026, are part of the company's strategy to enhance its workforce and are tied to the Nasdaq Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →TELA▼ -8.5%on this news
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
TELA Bio, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference. Scheduled for December 3rd, 2025, at 2:30 pm ET, the event will feature a presentation by TELA's management. Interested parties can access the webcast live or in archive. TELA Bio specializes in soft-tissue reconstruction solutions.
Read more →TELA▼ -10%on this newsshared move
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
TELA Bio reported a 9% increase in revenue for Q3 2025, driven by new customers and international sales. The company also announced a credit facility of up to $70 million to support growth. Despite a net loss of $8.6 million, TELA projects a revenue increase of at least 16% for the full year 2025. Strategic changes in leadership are contributing to improved performance.
Read more →TELATELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
TELA Bio, Inc. has announced a registered direct offering of 4,189,000 shares of its common stock, priced at $1.11 per share, and pre-funded warrants for 7,523,000 shares at $1.1099 each. The company expects to raise $13.0 million in gross proceeds, which will be allocated towards general corporate purposes such as sales, marketing, research, and development. The offering, managed by Nantahala Capital and EW Healthcare Partners, is anticipated to close on or about November 17, 2025, pending customary conditions. This move comes under an effective shelf registration statement with the SEC.
Read more →About TELA Bio, Inc.
Headquarters1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355
BIOPHARMAWATCH ELITE PLUS
Trade the next TELA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime